# Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

> **NCT00051025** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 9 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Lymphoma, B-cell
- Lymphoma, Low-grade

## Interventions

- **DRUG:** ONTAK

## Key facts

- **NCT ID:** NCT00051025
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2001-01
- **Final completion:** 2006-09
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2012-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051025, "Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00051025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*